COGT Cogent Biosciences, Inc.
Healthcare$33.94+3.89%ClosedMarket Cap: $5.80B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.62
P/S
0.00
EV/EBITDA
-15.41
DCF Value
$0.74
FCF Yield
-5.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-83.3%
ROA
-39.2%
ROIC
-42.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-103.6M | $-97.4M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-99.5M | $-102.5M | $— | — |
| FY null | $0.00 | -Infinity% | $-333.4M | $-328.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-83.4M | $-80.9M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-75.6M | $-73.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-74.9M | $-72.0M | $— | — |
| Q4 null | $0.00 | NaN% | $-73.7M | $-67.9M | $— | — |
| FY null | $0.00 | NaN% | $-275.9M | $-255.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-75.4M | $-70.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-64.4M | $-59.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-62.4M | $-58.3M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-58.2M | $-54.4M | $-0.63 | — |